Xarelto

Showing 14 posts of 74 posts found.

Bayer submits new Xarelto indications for European approval

January 6, 2011
Sales and Marketing Bayer, DVT, Xarelto, atrial fibrillation, deep vein thrombosis, pulmonary embolism, rivaroxaban, stroke prevention

Bayer is seeking European regulatory approval for a batch of new indications for its oral anticoagulant Xarelto. The company is …

Bayer rebrands pharma division

November 10, 2010
Medical Communications, Sales and Marketing Bayer Healthcare, Bayer cross, Byaer Schering Pharma, Marijn Dekkers, Xarelto, prix galien

The name Bayer Schering Pharma has been consigned to the corporate dustbin as its parent group institutes a branding shake-up. …

Bayer’s Xarelto hailed at Prix Galien

October 19, 2010
Research and Development Firazyr, Xarelto, prix galien

Bayer’s Factor Xa anticoagulant Xarelto scooped the Best Pharmaceutical Agent award at the prestigious Prix Galien ceremony. Xarelto is part …

Pradaxa, Xarelto and apixaban vie for attention

September 6, 2010
Research and Development, Sales and Marketing Pradaxa, Xarelto, apixaban, atrial fibrilation

New data has intensified the competition between three rival would-be cardiology blockbusters. Boehringer Ingelheim’s Pradaxa (dabigatran) and Bayer’s Xarelto (rivaroxaban) …

Novel anticoagulants set to lead atrial fibrillation market

July 9, 2010
Sales and Marketing Brinavess, Multaq, Pradaxa, Xarelto, apixaban, atrial fibrilation

Novel anticoagulants set to capture the atrial fibrillation market by 2019, according to a new report. Analysts Decision Resources say …

New anti-clotting drugs: stopping the silent killers

June 28, 2010
Research and Development, Sales and Marketing Pradaxa, VTE, Xarelto, atrial fibrilation, thrombosis

Blood clots are a major killer, but the threat they pose is poorly understood by the general public compared to …

Study boost for atrial fibrillation drugs

March 17, 2010
Research and Development Pradaxa, VTE, Xarelto, apixaban, betrixaban

Two rival drugs have both shown benefits over warfarin in patients with atrial fibrillation, according to new research. Boehringer Ingelheim’s …

Bayer pharma sales overcome European decline

February 26, 2010
Sales and Marketing 2009 financials, Bayer, Xarelto

Bayer’s group sales dropped 5% to 31 billion euros in a “difficult year” for the company that saw a drop …

NICE approves Bayer’s Xarelto

April 23, 2009
Research and Development Bayer, NICE, Xarelto

NICE has approved Bayer's anti-clotting treatment Xarelto, bringing it into line with Boehringer Ingelheim's rival Pradaxa. Xarelto (rivaroxaban) was assessed …

FDA to review Xarelto safety concerns

March 19, 2009
Research and Development, Sales and Marketing Xarelto

Anti-blood clotting drug Xarelto could fail to win approval in the US due to safety concerns. The FDA has convened …

Bayer’s ‘revolutionary’ anticoagulant Xarelto launched

November 4, 2008
Sales and Marketing Xarelto

Xarelto, the new anticoagulant treatment from Bayer has been launched in the UK, and is set to be among a …

The Pharmafocus Interview: Martin Dawkins

September 4, 2008
Research and Development, Sales and Marketing Bayer, Cancer, NICE, Xarelto, healthcare

 Martin Dawkins is an Englishman born and bred, but has spent most of his career working abroad, including the US, …

Bayer Schering blood clotting drug a ‘major leap forward’

December 14, 2007
Sales and Marketing Bayer, Xarelto, clot

Bayer Schering says its new blood clotting drug Xarelto is poised to set a new standard of care for post-surgery …

The Gateway to Local Adoption Series

Latest content